Matthew S. Milak, M.D.
Associate Professor of Psychiatry at the Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
Dr. Milak first became involved in neuroscience upon entering medical school, when he joined a group working on motor control in the context of adaptation to micro-gravity in animal models. After medical school he moved to the Barrow Neurological Institute (BNI) in Phoenix Arizona to study learning and memory in motor control. He became involved in human research and his interest shifted toward higher cognitive functions and their deficits in brain disorders. To pursue a career in clinical research studying the neurobiology of cognitive deficits in mental illness, he decided to complete residency training in psychiatry. After residency he joined the Columbia University Department of Psychiatry in July 2002 as a fellow. In 2006 he joined the faculty after obtaining a Career Development Grant from the NIMH. Since at Columbia Dr. Milak has been working on developing and applying molecular brain-imaging techniques in exploring the etiology and pathophysiology of psychiatric disorders. His current work focuses on the antidepressant mechanism of action of NMDA antagonists like ketamine.
Medical School: Semmelweis University, M.D., 1982 - 1989
Internship: Beth Israel University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, 1998 - 1999
Residency: Beth Israel University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, Psychiatry, 1999 - 2002
Fellowship: Department of Psychiatry Columbia University, College of Physicians and Surgeons, 2002 - 2005
Board Certifications: Diplomate of the American Board of Psychiatry and Neurology, 2002
• Treatment resistant mood and psychotic disorders.
Click here for Dr. Milak's Clinical Trials
NYS Psychiatric Institute
1051 Riverside Drive
New York, NY 10032
Utilizing molecular brain imaging techniques in the search of biomarkers, endophenotypes and their utility in diagnosing, understanding and predicting treatment outcome of major brain disorders.
1. Milak MS, Severance AJ, Ogden RT, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsey RV.: Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET.. J Nucl Med. 2008;49: 587-596
1. Milak, MS, Severance AJ, Prabhakaran J, Kumar JS, Majo VJ, Ogden RT, Mann JJ, Parsey RV.: In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer. . Journal of Cerebral Blood Flow and Metabolism 2011;31(1): 243-249
1. Milak, MS, Delorenzo C, Zanderigo F, Prabhakaran J, Kumar J, Majo VJ, Mann JJ, Parsey RV. : In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer.. Journal of Nuclear Medicine 2010;51(12): 1892-1900
1. Milak, MS, Keilp J, Parsey RV, Oquendo MA, Malone KM, Mann JJ. : Regional brain metabolic correlates of self-reported depression severity contrasted with clinician ratings. . Journal of Affective Disordersz 2010;126(1-2): 113-124
1. Milak MS, Parsey RV, Lee L, Oquendo MA, Olvet DM, Eipper F, Malone K, Mann JJ. : Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. . Psychiatry Research 2009;173(1): 63-70.